Gujarat Exclusive > National-World > 10 crore AstraZeneca-Oxford vaccine will be available by January: Adar Poonawalla

10 crore AstraZeneca-Oxford vaccine will be available by January: Adar Poonawalla

0
617

After AstraZeneca and the University of Oxford declared that their COVID-19 vaccine candidate has efficacy of upto 90 per cent with an average efficacy pegged at 70 per cent, Serum Institute of India (SII) chief Adar Poonawalla said that a minimum of 100 million doses of its vaccine ‘Covishield’ will be available by January for India.

Notably, Covishield has a cost advantage and is easier to store and transport as against other vaccine candidates developed by Pfizer and Moderna. It is also one of the major hopes for India which has recorded over 91 lakh cases of the virus and a death toll surpassing 1.31 lakh.

Poonawalla said that 40 million doses of the vaccine have been already produced and the Centre will procure the stock at a rate of Rs 250 or less. The SII chief said the vaccine would be available in the private market at a price of Rs 500-Rs 600. The pricing for the private market has been kept in such a way that the distributors will make some money, he said.

AstraZeneca reveals vaccine’s efficacy

On Monday morning, AstraZeneca and the University of Oxford announced that their vaccine candidate has shown an average efficacy of 70 per cent in clinical trials. It is much lower than the efficacy of over 90 exhibited by the vaccine candidates developed by Pfizer and Moderna.

Also Read: AstraZeneca-Oxford vaccine shows average efficacy of 70%

AstraZeneca clarified that one dosing regimen showed vaccine efficacy of 90 per cent when the vaccine was given as a half dose, followed by a full dose at least one month apart. Another dosing regimen showed 62 per cent efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens resulted in an average efficacy of 70%

Vaccine safe to use

An independent Data Safety Monitoring Board determined that the analysis met its primary endpoint showing protection from COVID-19 occurring 14 days or more after receiving two doses of the vaccine. No serious safety events related to the vaccine have been confirmed. The vaccine was well tolerated across both dosing regimens.

AstraZeneca will now immediately prepare regulatory submission of the data to authorities around the world that have a framework in place for conditional or early approval. It will seek an Emergency Use Listing from the World Health Organisation for an accelerated pathway to vaccine availability in low-income countries.

 

To read the latest news in Gujarati click here